Legend Biotech (LEGN) Change in Receivables (2020 - 2026)

Legend Biotech (LEGN) has reported Change in Receivables for 7 consecutive years, with $11.4 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Receivables rose 93.22% year-over-year to $11.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.9 million (up 479.11% YoY) and the FY2024 annual result came in at $93.8 million, up 194.72% from the prior year.
• Change in Receivables fell to $11.4 million in Q1 2026 per LEGN's latest filing, from $25.8 million in the prior quarter.
• Over the last five years, Change in Receivables for LEGN reached as high as $96.7 million in Q1 2024 and fell as low as -$99.0 million in Q4 2023.
• A 5-year average of $3.9 million and a median of $218500.0 in 2022 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2023 — Change in Receivables tumbled 319416.13% — and 2024, when it surged 284411.76%.
• Year by year, Change in Receivables stood at -$31000.0 in 2022, then slumped by 319416.13% to -$99.0 million in 2023, then surged by 94.36% to -$5.6 million in 2024, then surged by 562.02% to $25.8 million in 2025, then slumped by 55.8% to $11.4 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $11.4 million, $25.8 million, and -$26.2 million for Q1 2026, Q3 2025, and Q2 2025 respectively.